Study identifier:D169DC00001
ClinicalTrials.gov identifier:NCT04564742
EudraCT identifier:2020-000664-31
CTIS identifier:N/A
A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure
Acute Myocardial Infarction
Phase 3
No
Dapagliflozin, Placebo
All
4017
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
Uppsala Clinical Research Center
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Dapagliflozin Patients will be randomized 1:1 to either dapagliflozin or placebo | Drug: Dapagliflozin Dapagliflozin 10 mg tablets given once daily, per oral use Other Name: Forxiga TM Other Name: Farxiga TM |
Placebo Comparator: Placebo Placebo matching dapagliflozin | Drug: Placebo Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use |